《异动》药捷安康初段炒高 16% 日前建议实行 H 股全流通

TRANSTHERA-B (02617.HK) opened down 2.1% this morning (22nd) but quickly reversed to rise sharply, currently reported at HKD 201.2, up 16.5%, with a transaction volume of HKD 529 million.

The group announced on Monday that the board has considered and approved the submission of an application to the China Securities Regulatory Commission to convert 44.97 million domestic shares held by 10 shareholders into H shares, accounting for approximately 11.33% of the company's currently issued share capital. Upon obtaining all relevant approvals, these domestic shares will be converted into H shares and will qualify for listing and trading on the main board of the Stock Exchange. According to the company's articles of association, there is no need to hold a shareholders' meeting to approve the conversion and listing.

The stock was listed in late June and had not recorded any revenue for the half-year ending in June, with a loss of RMB 123 million, compared to a loss of RMB 160 million in the previous fiscal year. The stock had surged over 50 times within less than three months of listing, with the share price peaking at HKD 679.5 in mid-September, and its market value once exceeding HKD 200 billion, even surpassing pharmaceutical blue chips such as China National Pharmaceutical Group (01177.HK) and Stone Pharmaceutical (01093.HK), before sharply declining